High Yield Production of a Soluble Human Interleukin-3 Variant from E. coli with Wild-Type Bioactivity and Improved Radiolabeling Properties

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Hercus, Timothy R ^a   Barry, Emma F ^a   Dottore, Mara ^a   McClure, Barbara J ^a   Webb, Andrew I ^b,c   Lopez, Angel F ^a   Young, Ian G ^d   Murphy, James M ^b,c  

^a CENTRE FOR CANCER BIOLOGY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Biology and Environment   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 3;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; ISOTOPE LABELING; MASS SPECTROMETRY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RADIOIODINATION; RECEPTOR BINDING; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CHROMATOGRAPHY, REVERSE-PHASE; DNA PRIMERS; ESCHERICHIA COLI; HUMANS; INTERLEUKIN-3; MASS SPECTROMETRY; MICE; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; SOLUBILITY;

EID: 84883140800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074376     Document Type: Article

References (41)

1. Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, et al. (2012) The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev 250: 277-302. doi:10.1111/j.1600-065X.2012.01164.x. PubMed: 23046136.
2. Lopez AF, Lyons AB, Eglinton JM, Park LS, To LB, et al. (1990) Specific binding of human interleukin-3 and granulocyte-macrophage colony-stimulating factor to human basophils. J Allergy Clin Immunol 85: 99-102. doi:10.1016/0091-6749(90)90229-W. PubMed: 2153721.
3. Robin C, Ottersbach K, Durand C, Peeters M, Vanes L, et al. (2006) An unexpected role for IL-3 in the embryonic development of hematopoietic stem cells. Dev Cell 11: 171-180. doi:10.1016/j.devcel.2006.07.002. PubMed: 16890157.
4. Yamada T, Sun Q, Zeibecoglou K, Bungre J, North J, et al. (1998) IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells. J Allergy Clin Immunol 101: 677-682. doi:10.1016/S0091-6749(98)70177-0. PubMed: 9600506.
5. Lantz CS, Boesiger J, Song CH, Mach N, Kobayashi T, et al. (1998) Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 392: 90-93. doi:10.1038/32190. PubMed: 9510253.
6. Ohmori K, Luo Y, Jia Y, Nishida J, Wang Z, et al. (2009) IL-3 induces basophil expansion in vivo by directing granulocyte-monocyte progenitors to differentiate into basophil lineage-restricted progenitors in the bone marrow and by increasing the number of basophil/mast cell progenitors in the spleen. J Immunol 182: 2835-2841. doi:10.4049/jimmunol.0802870. PubMed: 19234178.
7. Clanchy FI, Hamilton JA, (2013) The development of macrophages from human CD34+ haematopoietic stem cells in serum-free cultures is optimized by IL-3 and SCF. Cytokine 61: 33-37. doi:10.1016/j.cyto.2012.09.005. PubMed: 23040055.
8. Dahl C, Hoffmann HJ, Saito H, Schiøtz PO, (2004) Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured in vitro. Allergy 59: 1087-1096. doi:10.1111/j.1398-9995.2004.00606.x. PubMed: 15355468.
9. Lopez AF, Eglinton JM, Lyons AB, Tapley PM, To LB, et al. (1990) Human interleukin-3 inhibits the binding of granulocyte-macrophage colony-stimulating factor and interleukin-5 to basophils and strongly enhances their functional activity. J Cell Physiol 145: 69-77. doi:10.1002/jcp.1041450111. PubMed: 1698795.
10. Delwel R, Dorssers L, Touw I, Wagemaker G, Löwenberg B, (1987) Human recombinant multilineage colony stimulating factor (interleukin-3): stimulator of acute myelocytic leukemia progenitor cells in vitro. Blood 70: 333-336. PubMed: 2439154.
11. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C, (1999) Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A 96: 12804-12809. doi:10.1073/pnas.96.22.12804. PubMed: 10536003.
12. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, et al. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5: 31-42. doi:10.1016/j.stem.2009.04.018. PubMed: 19570512.
13. Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, et al. (2002) Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 100: 2980-2988. doi:10.1182/blood-2002-03-0852. PubMed: 12351411.
14. Chen J, Olsen J, Ford S, Mirza S, Walker A, et al. (2009) A new isoform of interleukin-3 receptor {alpha} with novel differentiation activity and high affinity binding mode. J Biol Chem 284: 5763-5773. PubMed: 19109256.
15. Lopez AF, Hercus TR, Ekert P, Littler DR, Guthridge M, et al. (2010) Molecular basis of cytokine receptor activation. IUBMB Life 62: 509-518. doi:10.1002/iub.350. PubMed: 20540154.
16. Murphy JM, Young IG, (2006) IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. Vitam Horm 74: 1-30. doi:10.1016/S0083-6729(06)74001-8. PubMed: 17027509.
17. Olins PO, Bauer SC, Braford-Goldberg S, Sterbenz K, Polazzi JO, et al. (1995) Saturation mutagenesis of human interleukin-3. J Biol Chem 270: 23754-23760. doi:10.1074/jbc.270.40.23754. PubMed: 7559548.
18. Murphy JM, Metcalf D, Young IG, Hilton DJ, (2010) A convenient method for preparation of an engineered mouse interleukin-3 analog with high solubility and wild-type bioactivity. Growth Factors 28: 104-110. doi:10.3109/08977190903443048. PubMed: 19961363.
19. Wiśniewski JR, Zougman A, Nagaraj N, Mann M, (2009) Universal sample preparation method for proteome analysis. Nat Methods 6: 359-362. doi:10.1038/nmeth.1322. PubMed: 19377485.
20. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, et al. (1989) Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 140: 323-334. doi:10.1002/jcp.1041400219. PubMed: 2663885.
21. Murphy JM, Soboleva TA, Mirza S, Ford SC, Olsen JE, et al. (2008) Clarification of the role of N-glycans on the common beta-subunit of the human IL-3, IL-5 and GM-CSF receptors and the murine IL-3 beta-receptor in ligand-binding and receptor activation. Cytokine 42: 234-242. doi:10.1016/j.cyto.2008.02.010. PubMed: 18374598.
22. Mirza S, Walker A, Chen J, Murphy JM, Young IG, (2010) The Ig-like domain of human GM-CSF receptor alpha plays a critical role in cytokine binding and receptor activation. Biochem J 426: 307-317. doi:10.1042/BJ20091745. PubMed: 20078425.
23. Murphy JM, Ford SC, Olsen JE, Gustin SE, Jeffrey PD, et al. (2004) Interleukin-3 binding to the murine betaIL-3 and human betac receptors involves functional epitopes formed by domains 1 and 4 of different protein chains. J Biol Chem 279: 26500-26508. doi:10.1074/jbc.M402705200. PubMed: 15060062.
24. Woodcock JM, Bagley CJ, Zacharakis B, Lopez AF, (1996) A single tyrosine residue in the membrane-proximal domain of the granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptor common beta-chain is necessary and sufficient for high affinity binding and signaling by all three ligands. J Biol Chem 271: 25999-26006. doi:10.1074/jbc.271.42.25999. PubMed: 8824238.
25. Tropea JE, Cherry S, Waugh DS, (2009) Expression and purification of soluble His(6)-tagged TEV protease. Methods Mol Biol 498: 297-307. doi:10.1007/978-1-59745-196-3_19. PubMed: 18988033.
26. Feng Y, Klein BK, McWherter CA, (1996) Three-dimensional solution structure and backbone dynamics of a variant of human interleukin-3. J Mol Biol 259: 524-541. doi:10.1006/jmbi.1996.0337. PubMed: 8676386.
27. Fraker PJ, Speck JC Jr., (1978) Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 80: 849-857. doi:10.1016/0006-291X(78)91322-0. PubMed: 637870.
28. Yang YC, Ciarletta AB, Temple PA, Chung MP, Kovacic S, et al. (1986) Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 47: 3-10. doi:10.1016/0092-8674(86)90360-0. PubMed: 3489530.
29. Ding H, Griesel C, Nimtz M, Conradt HS, Weich HA, et al. (2003) Molecular cloning, expression, purification, and characterization of soluble full-length, human interleukin-3 with a baculovirus-insect cell expression system. Protein Expr Purif 31: 34-41. doi:10.1016/S1046-5928(03)00138-4. PubMed: 12963338.
30. Li H, Li N, Gao X, Kong X, Li S, et al. (2011) High level expression of active recombinant human interleukin-3 in Pichia pastoris. Protein Expr Purif 80: 185-193. doi:10.1016/j.pep.2011.08.027. PubMed: 21907288.
31. Nowruzi K, Elkamel A, Scharer JM, Cossar D, Moo-Young M, (2008) Development of a minimal defined medium for recombinant human interleukin-3 production by Streptomyces lividans 66. Biotechnol Bioeng 99: 214-222. doi:10.1002/bit.21566. PubMed: 17615562.
32. Westers L, Dijkstra DS, Westers H, van Dijl JM, Quax WJ, (2006) Secretion of functional human interleukin-3 from Bacillus subtilis. J Biotechnol 123: 211-224. doi:10.1016/j.jbiotec.2005.11.007. PubMed: 16359746.
33. Boyle DM, McKinnie RE, Joy WD, Violand BN, McLaughlin JK, et al. (1999) Evaluation of refolding conditions for a recombinant human interleukin-3 variant (daniplestim). Biotechnol Appl Biochem 30(2):: 163-170. PubMed: 10512796.
34. de Marco A, (2006) Two-step metal affinity purification of double-tagged (NusA-His6) fusion proteins. Nat Protoc 1: 1538-1543. doi:10.1038/nprot.2006.289. PubMed: 17406446.
35. De Marco V, Stier G, Blandin S, de Marco A, (2004) The solubility and stability of recombinant proteins are increased by their fusion to NusA. Biochem Biophys Res Commun 322: 766-771. doi:10.1016/j.bbrc.2004.07.189. PubMed: 15336530.
36. Yao S, Hinds MG, Murphy JM, Norton RS, (2011) Exchange enhanced sensitivity gain for solvent-exchangeable protons in 2D 1H-15N heteronuclear correlation spectra acquired with band-selective pulses. J Magn Reson 211: 243-247. doi:10.1016/j.jmr.2011.05.013. PubMed: 21683633.
37. Yao S, Murphy JM, Low A, Norton RS, (2010) 1H, 13C and 15N resonance assignments of a highly-soluble murine interleukin-3 analogue with wild-type bioactivity. Biomol NMR Assign 4: 73-77. doi:10.1007/s12104-010-9213-1. PubMed: 20174897.
38. Yao S, Young IG, Norton RS, Murphy JM, (2011) Murine interleukin-3: structure, dynamics, and conformational heterogeneity in solution. Biochemistry 50: 2464-2477. doi:10.1021/bi101810f. PubMed: 21329364.
39. Dudley A, McKinstry W, Thomas D, Best J, Jenkins A, (2003) Removal of endotoxin by reverse phase HPLC abolishes anti-endothelial cell activity of bacterially expressed plasminogen kringle 5. BioTechniques 35: 724-726.passim PubMed: 14579737.
40. Stomski FC, Woodcock JM, Zacharakis B, Bagley CJ, Sun Q, et al. (1998) Identification of a Cys motif in the common beta chain of the interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 receptors essential for disulfide-linked receptor heterodimerization and activation of all three receptors. J Biol Chem 273: 1192-1199. doi:10.1074/jbc.273.2.1192. PubMed: 9422786.
41. Klein BK, Olins PO, Bauer SC, Caparon MH, Easton AM, et al. (1999) Use of combinatorial mutagenesis to select for multiply substituted human interleukin-3 variants with improved pharmacologic properties. Exp Hematol 27: 1746-1756. doi:10.1016/S0301-472X(99)00118-6. PubMed: 10641592.